Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors

DOI: 10.5306/wjco.v8.i4.320

Keywords: Predictive biomarkers, Immunotherapy, Checkpoint inhibitors, Programmed cell death protein ligand 1, Non-small cell lung cancer

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text